Business Wire·Nov 12, 2026, 4:05 PM ET

Sensus Healthcare Reports Third Quarter 2026 Financial Results and Business Highlights

SRTS

Sensus Healthcare reported Q3 2026 revenues of $6.0 million, down 13% from $6.9 million in Q3 2025 due to a product mix shift toward lower-priced SRT-100 systems, the absence of sales to a historically large customer, and revenue recognition timing for Fair Deal Agreement units.
Gross profit increased to $3.3 million from $2.7 million in the prior-year period, with gross margin improving to 55% from 39.1% driven by higher shipments of higher-margin SRT-100 units.
The company shipped 26 systems during the quarter, including eight carried over from Q2, compared to 16 units in Q3 2025, representing 18 new shipments excluding the carry-over units.
Management expanded its customer base through initial purchases by two large private equity-backed dermatology groups, while launching TreatSkinCancer.com to increase patient awareness.
International market development advanced across Asia-Pacific regions, including Australia, New Zealand, China, and Hong Kong.
The company achieved a commercial milestone by placing its 1,000th SRT system subsequent to the quarter's end.
Net loss for the quarter was $1.5 million ($0.09 per share), compared to a net loss of $0.9 million ($0.06 per share) in Q3 2025.
Adjusted EBITDA improved to a negative $1.5 million from a negative $2.4 million in the prior-year period.
Cash, restricted cash, and cash equivalents totaled $12.9 million as of September 30, 2026, with no outstanding borrowings under the revolving line of credit.
General and administrative expenses rose to $2.3 million due to higher legal fees, while research and development expenses decreased to $1.1 million due to reduced lobbying costs and headcount.